Recent Finacing
Recent Raise
Excision BioTherapeutics develops CRISPR-based therapies to remove viral genomes, advancing EBT-101 into Phase 1/2 for chronic HIV and preclinical programs targeting JC virus, HSV, and HBV.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
